Gaudium IVF introduces AI-led infertility treatment, marking an industry first in India

Gaudium IVF, an innovation leader and a pioneering force in India’s fertility healthcare sector, has introduced artificial intelligence (AI)-led infertility treatment, marking yet another industry first—just one month after becoming India’s first publicly listed IVF chain.

The development involves the integration of advanced AI-driven embryology systems, including SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant), into routine clinical practice. This milestone was formally inaugurated by Hon’ble Union Minister Nitin Jairam Gadkari, Minister for Road Transport and Highways, Government of India, who emphasised the role of innovation and technology in shaping the nation’s future.

This integration has been undertaken in collaboration with IVF 2.0, a UK-headquartered embryology innovation organisation founded by renowned embryologists Dr Jacques Cohen and Dr Alejandro Chave. This partnership brings globally advanced embryology intelligence into the Indian clinical ecosystem.

Speaking at the inauguration, Union Minister Nitin Jairam Gadkari, Minister for Road Transport and Highways, Government of India, remarked, “The adoption of advanced technologies such as artificial intelligence reflects India’s growing strength in innovation. Initiatives like these will play an important role in shaping the future of technology-led solutions across sectors.”

Commenting on the development, Dr Manika Khanna, Chairperson and Managing Director, Gaudium IVF, said, “Fertility care is entering a new era where precision and intelligence will define outcomes. By integrating AI into infertility treatment, Gaudium IVF is not only improving success rates but also bringing greater predictability, transparency, and trust to the patient journey. Our collaboration with IVF 2.0 ensures that global innovations are now accessible to patients within India.”

Speaking about the collaboration, Giles Palmer, Clinical Scientist and Director of Global Communications, IVF 2.0 stated, “Our focus has always been to translate embryology intelligence into measurable clinical outcomes. Partnering with Gaudium IVF allows us to bring our AI-driven solutions into a high-growth market like India and set new benchmarks for how reproductive medicine is practised.

The newly introduced technologies are designed to enhance critical stages of the IVF process. SiD or Sperm Identification Device is an advanced AI system designed to optimise sperm selection during fertility treatments. By analysing various sperm movement parameters, SID identifies the most viable sperm for fertilisation, which can lead to better-quality blastocyst formation. Complementing this, ERICA or Embryo Ranking Intelligent Classification Assistant, an advanced AI-powered tool designed to support embryologists in embryo selection, provides objective, data-driven ranking of embryos. It is done by analysing static images of blastocysts based on key morphological and developmental characteristics.

Together, these non-invasive tools assist embryologists in improving decision-making and reducing variability.

Early clinical observations suggest that the integration of these AI systems can significantly improve fertilisation and blastocyst development rates. By improving precision and consistency, the adoption of AI has the potential to reduce the need for repeat cycles, thereby lowering the emotional, physical, and financial burden on patients while inspiring confidence among clinicians and stakeholders.